Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
NCT ID: NCT04711265
Last Updated: 2021-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
176 participants
OBSERVATIONAL
2015-09-30
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls
NCT04920526
A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years
NCT01446718
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
NCT05435209
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
NCT04772534
IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody
NCT01206556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
Intramuscular injection with 3 doses of QHPV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* participated in primary immunogenicity study
* consent/assent with parental consent for participants age \<18 years
* willing to continue extended follow up for 36 months
Exclusion Criteria
9 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Washington
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
Kenya Medical Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nelly Rwamba Mugo
Senior Principal Clinical Research Scientist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Partners in Health Research and Development
Thika, Kiambu County, Kenya
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KENYAMRI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.